These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 21330402

  • 1. Which oral agent to use when metformin is no longer effective?
    Bannon M.
    QJM; 2011 Mar; 104(3):183-4. PubMed ID: 21330402
    [No Abstract] [Full Text] [Related]

  • 2. What to add in with metformin in type 2 diabetes?
    Petrie JR, Adler A, Vella S.
    QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663
    [Abstract] [Full Text] [Related]

  • 3. The backbone of oral glucose-lowering therapy: time for a paradigm shift?
    Seufert J.
    Fundam Clin Pharmacol; 2009 Dec; 23(6):651-67. PubMed ID: 19469803
    [Abstract] [Full Text] [Related]

  • 4. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE.
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A, Borot S, Raccah D.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Which oral drug is right for your type 2 diabetes? New thinking on oral drug combinations that can provide better glycemic control.
    Health News; 2005 Feb; 11(2):10-1. PubMed ID: 15732153
    [No Abstract] [Full Text] [Related]

  • 11. [Antidiabetic Drugs and the Kidney].
    Candido R.
    G Ital Nefrol; 2005 Feb; 33(S68):. PubMed ID: 27960013
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Beyond insulin replacement: addressing the additional needs of the diabetes patient.
    Dailey G.
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():83-97. PubMed ID: 18577160
    [Abstract] [Full Text] [Related]

  • 15. Diabetes under control: Understanding oral antidiabetic agents.
    Longo R.
    Am J Nurs; 2010 Feb; 110(2):49-52. PubMed ID: 20107402
    [No Abstract] [Full Text] [Related]

  • 16. [Drug treatment of type 2 diabetes].
    Tielmans A, Laloi-Michelin M, Coupaye M, Virally M, Meas T, Guillausseau PJ.
    Presse Med; 2007 Feb; 36(2 Pt 2):269-78. PubMed ID: 17258675
    [Abstract] [Full Text] [Related]

  • 17. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
    Pratley RE.
    J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.